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Economic evaluation of concise Cognitive Behavioural Therapy and/or
pharmacotherapy for depressive and anxiety disorders
Abstract

BACKGROUND: Depressive and anxiety disorders cause great suffering and disability and are associated
with high health care costs. In a previous conducted pragmatic randomised controlled trial, we have shown
that a concise format of cognitive behavioural- and/or pharmacotherapy is as effective as standard care in
reducing depressive and anxiety symptoms and in improving subdomains of general health and quality of life
in secondary care psychiatric outpatients. AIMS OF THE STUDY: In this economic evaluation, we
examined whether a favourable cost-utility of concise care compared to standard care was attained.
METHODS: The economic evaluation was performed alongside a pragmatic randomised controlled trial.
Health-related quality of life was measured using the Short-Form (SF-36) questionnaire. Cost of healthcare
utilization and productivity loss (absenteeism and presenteeism) were assessed using the Trimbos/iMTA
questionnaire for Costs associated with Psychiatric Illness (TiC-P). A cost-utility analysis, using costeffectiveness acceptability curves, comparing differences in societal costs and Quality-Adjusted Life Years
(QALYs) at 1 year was performed. RESULTS: One year after study entry, the difference in mean cost per
patient of the two primary treatments was not significant between both groups. No significant differences in
other healthcare and non- healthcare costs could be detected between patients receiving concise care and
standard care. Also, QALYs were not statistically different between the groups during the study period. From
both the societal and healthcare perspective, the probability that concise care is more cost-effective compared
to standard care remains below the turning point of 0.5 for all acceptable values of the willingness to pay for a
QALY. The economic evaluation suggests that concise care is unlikely to be cost-effective compared to
standard care in the treatment for depressive- and anxiety disorders in secondary mental health care during a
one year follow up period. DISCUSSION: Total costs and QALYs were not significantly different between
standard and concise care, with no evidence for cost-effectiveness of concise care in the first year. The longer
impact of concise care for patients with mild to moderate symptoms of depressive and/or anxiety disorders
compared to standard care in secondary care needs to be further studied. IMPLICATIONS: This economic
evaluation failed to find significant differences in cost between concise and standard care over the study period
of one year. Replication of our economic evaluation might benefit from an extended follow-up period and
strict adherence to the study protocol. If concise care will be found to be cost-effective in the long term, this
would have major implications for recommendations how to optimize secondary mental health care in the
treatment of depressive - and anxiety disorders.
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Abstract
Background: Depressive and anxiety disorders cause great suffering and disability and are associated with
high health care costs. In a previous conducted pragmatic randomised controlled trial, we have shown that a
concise format of cognitive behavioural- and/or pharmacotherapy is as effective as standard care in
reducing depressive and anxiety symptoms and in improving subdomains of general health and quality of
life in secondary care psychiatric outpatients.
Aims of the Study: In this economic evaluation, we examined whether a favourable cost-utility of concise
care compared to standard care was attained.
Methods: The economic evaluation was performed alongside a pragmatic randomised controlled trial.
Health-related quality of life was measured using the Short-Form (SF-36) questionnaire. Cost of healthcare
utilization and productivity loss (absenteeism and presenteeism) were assessed using the Trimbos/iMTA
questionnaire for Costs associated with Psychiatric Illness (TiC-P). A cost-utility analysis, using costeffectiveness acceptability curves, comparing differences in societal costs and Quality-Adjusted Life Years
(QALYs) at 1 year was performed.
Results: One year after study entry, the difference in mean cost per patient of the two primary treatments
was not significant between both groups. No significant differences in other healthcare and non- healthcare
costs could be detected between patients receiving concise care and standard care. Also, QALYs were not
statistically different between the groups during the study period. From both the societal and healthcare
perspective, the probability that concise care is more cost-effective compared to standard care remains
below the turning point of 0.5 for all acceptable values of the willingness to pay for a QALY. The
economic evaluation suggests that concise care is unlikely to be cost-effective compared to standard care
in the treatment for depressive- and anxiety disorders in secondary mental health care during a one year
follow up period.
Discussion: Total costs and QALYs were not significantly different between standard and concise care,
with no evidence for cost-effectiveness of concise care in the first year. The longer impact of concise care
for patients with mild to moderate symptoms of depressive- and/or anxiety disorders compared to standard
care in secondary care needs to be further studied.
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Implications : This economic evaluation failed to find significant differences in cost between concise and
standard care over the study period of one year. Replication of our economic evaluation might benefit from
an extended follow-up period and strict adherence to the study protocol. If concise care will be found to be
cost-effective in the long term, this would have major implications for recommendations how to optimize
secondary mental health care in the treatment of depressive- and anxiety disorders.

Keywords: Cost-effectiveness, Routine Outcome Monitoring, Randomised controlled trial, Concise care,
Secondary care, Anxiety, Depression, Healthcare utilization
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Introduction
Depressive and anxiety disorders are highly prevalent in clinical practice, causing great
suffering and disability, and having a considerable impact on individuals, health services
and society.1-3 Several psycho- and pharmacotherapeutic treatments are widely applied
and have been shown to provide adequate treatment for these disorders. However, they
place an increased demand on health and social care resources, causing a considerable
economic burden.4-6 Offering these treatments in a more concise form, in which
treatments are confined to a maximum number of sessions within a fixed time-period, can
yield savings in both healthcare and societal costs. As a result, costs of treatment could be
lowered while maintaining clinical effectiveness, resulting in a favourable costeffectiveness of concise care compared to standard care.
In a recent pragmatic randomised controlled trial,7 we compared a concise, time restricted
approach of psycho- and/or pharmacotherapy with standard routine care in the treatment
of secondary care outpatients with an anxiety- and/or depressive disorder. Both standard
and concise care equally succeeded in reducing depressive- and anxiety complaints and
improved current general health status and subdomains of quality of life (e.g. functional
status and physical functioning) during the first year after study entry. We concluded that
a concise format of psycho- and/or pharmacotherapy is as effective as standard care in the
treatment of outpatients with a mild to moderate depressive- and/or anxiety disorders (see
Meuldijk (2015) and colleagues).8 In addition, since health care budgets are shrinking, an
economic evaluation of this effect is desired to inform decisions which health care
services to offer. This paper reports about the cost-effectiveness (cost-utility) of concise
care versus standard care. We performed an economic evaluation based on the data of our
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randomised controlled trial,8 to determine whether, given the similar clinical
effectiveness, a favourable cost-effectiveness for concise care is attained, one year after
study entry.
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Methods
Study Design
An economic evaluation was embedded in a pragmatic, randomised controlled trial of
equivalence examining the effectiveness of concise care in patients with a mild to
moderate anxiety- and/or depressive disorder.7 The study was approved by the Medical
Ethical Committee (MEC) of the Leiden University Medical Centre (LUMC) and adhered
to the consolidated standards for reporting randomised controlled equivalence trials.9-11
The trial was conducted at five Dutch outpatient Mental Healthcare Centres (MHCs) of
the Regional Mental Health Provider (RMHP) Rivierduinen. In short, between March
2010 and December 2012, 182 patients were enrolled. These patients (aged 18-65 years)
with a mild to moderate anxiety- and/or depressive disorder were randomly allocated to
concise or standard care. Patients with suicidal or homicidal risk, severe social
dysfunction, delusions, hallucinations and/or suffering from bipolar or psychotic
disorders were excluded from the trial. Co-morbidity with other psychiatric disorders was
allowed. Patients’ progress and clinical effectiveness of treatment were assessed by
touch-screen Routine Outcome Monitoring (ROM), and planned at baseline (T1), 3
months (T2), 6 (T3) and 12 (T4) months after baseline. Written informed consent was
obtained from all participants before study entry. The baseline characteristics of both
groups were similar.8 Details on the methodology and design of this randomised clinical
trial and the clinical effectiveness results are reported elsewhere.7,8
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Treatments
In both concise and standard care, a choice could be made between pharmacotherapy
with a selective serotonin reuptake inhibitor (SSRI)13 or psychotherapy with Cognitive
Behavioural Therapy (CBT)14,15 or, in case of a posttraumatic stress disorder, Eye
Movement Desensitization and Reprocessing-therapy (EMDR).16 Concise care is
characterized by a quick onset, a fixed number of weekly sessions (maximum of 7
sessions) within a 7-week fixed time period after which concise care ends. If
insufficiently helped by this initial treatment, continuation of (additional) treatment,
according to the stepped-care principles,17-19 was possible.
Standard care is not confined to a maximum number of sessions or within a fixed timeperiod and could continue during the entire study period of 1 year. The treatment
protocols in concise and standard care followed the Dutch guidelines for the evidencebased treatment of depressive and anxiety disorders,17 thereby advocating a stepped-care
approach.18,19 Details of the treatment can be found elsewhere.7

Measures
The information for the economic evaluation was captured during the entire study period
of one year. Generic health-related quality of life was assessed with the Short Form-36
Health Survey (SF-36)20,21 at baseline and at the subsequent follow-up measurements.
Use of medical resources and productivity loss were assessed with the Trimbos/iMTA
questionnaire for Costs associated with Psychiatric Illness (TiC-P),22,23 3, 6 and 12
months after baseline.
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Quality of life
The SF-3620,21 is a 36-item self-report questionnaire that measures health status in eight
domains: physical functioning, social functioning, physical problems, emotional
problems, mental health, vitality, bodily pain and general health. The SF-36 has good
psychometric properties and is proven useful in differentiating the health benefits
produced by a wide range of different treatments. The SF-36 scores were used to
calculate utilities.24 These represent the societal valuation of the health-related quality of
life of the patients on a scale from ‘0’ (‘as bad as death’) to ‘1’ (‘perfect health’). Qualityadjusted life-years (QALYs) were estimated by applying the area-under-the-curve
method. QALYs take into account both the quantity and quality of life generated by
health care interventions and offer the possibility of comparison of the impact with other
medical interventions, which is preferred for economic evaluations.25,26

Healthcare and non-healthcare costs
The economic evaluation was undertaken from a societal perspective, and included costs
due to health care resource utilisation (healthcare costs) and costs attributable to
production losses (non-healthcare cost). Data on costs of primary treatment (either
standard or concise care) were assessed from case-record forms in which type of contact
(face-to-face, telephone, e-mail), type of visit (psychologist, psychiatrist,
psychotherapists, and other) and time per contact was collected, directly from the
participating centres. Costs of crisis therapy/contacts were also included. Other healthcare
and non-healthcare costs from the patients were collected using the TiC-P
questionnaire.22,23 The first part of the TiC-P measures medical resource utilization by
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asking for the number of contacts with different (para)medical and psychological healthcare providers (e.g. general practitioner (GP), psychiatrist, medical specialist,
physiotherapist, alternative health practitioner, day care/hospital length of stay) during
the past 4 weeks.22 When calculating the costs, it was assumed that the number of
contacts and/or days in those 4 weeks to be representative for the total period between
assessments (i.e.: 3 months between T1 – T2, 3 months between T2- T3, 6 months between
T3- T4). To estimate health service use over the total period, we interpolated the
frequencies of contacts within these four weeks, to the total observed period between
assessments. The number of medical contacts were multiplied by reference unit costs of
the corresponding health care services. All costs were adjusted to the year 2013 according
to the consumer price index27 and are presented in euros. The TiC-P questionnaire was
adjusted for the current study: open-ended questions were categorized to be suitable using
the touch screen ROM method (e.g. ‘How often did you visit the GP in the past 4
weeks?’: 1 time, 2 to 5 times, 5 to 10 times, 10 times or more). Absence from work,
reduced efficiency at work, difficulties with job performance (absenteeism from paid
work), and production losses without absenteeism from paid work (e.g. presenteeism) are
measured in the second part of the TiC-P. Work absenteeism is measured by two
questions related to short- and long-term absence (< 2 weeks and > 2 weeks) from work.
For the current study, only data on short-term absence was available. Again, we
interpolated the short-term absence to the total time period between two assessments.
Costs of absenteeism from paid work were calculated according to the Friction Cost (FC)
method.28 With this method, the number of hours patients were absent from their job is
multiplied with the actual gross wage per hour for the duration of the friction period, i.e.
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the timespan organisations need to restore the initial production level. In the Netherlands,
the friction period is set at 23 weeks.29
Presenteeism is measured by asking patients how many days at work their health
problems hinders their performance while at work and their efficiency on these days,
scored on a scale ranging from ‘0’ (could not do anything) to ‘10’ (able to do as much as
normally). Presenteeism costs were calculated by weighing the number of working days
impaired by the efficiency score and interpolating these estimates of productivity loss due
to presenteeism in the past 2 weeks to the total time period between two assessments
(assuming 240 eligible work days/year).

Data Analytic Procedures
All analyses followed the intention-to-treat principle. A total of 182 patients participated
in the randomized controlled trial and were randomised to either standard care (n=89) or
concise care (n=93). Full economic and outcome data were available at T2, T3, and T4 for
respectively 57%, 36% and 23% of the total patients (CONSORT Flow of participants
diagram see Meuldijk (2015) and colleagues).8 To impute missing cost and effect data,
Multiple Imputation (MI) according to the Multivariate Imputation by Chained Equations
(MICE) algorithm with 10 iterations for the switching regression model was done.30,31
Differences in (societal) costs were compared between both groups for the total number
of 182 patients. In the cost-utility analysis societal costs and QALYs based on the SF-36
from the start of the study until the end of the first year were compared. Subsequently,
cost-effectiveness acceptability curves (CEACs) were constructed. They represent the
probability that, given a certain threshold for the willingness to pay for a QALY, concise

9

care is cost-effective in comparison with standard care. Cost-effectiveness is plausible,
when the probability that concise care is effective exceeds 0.5 for a given willingness-topay. The Dutch economic threshold for willingness to pay is assumed to be between
€20,000 and €80,000 per QALY.32,33 Cost analyses were conducted with Stata 9.2 (Stata
Corp, College Station, Texas, USA) and IBM SPSS version 20 for Windows (SPSS Inc.,
Chicago, IL, USA).
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Results
The study design planned assessments to be performed at baseline, 3, 6, and 12-months
post-baseline, referred to as respectively T1, T2, T3 and T4. Due to the pragmatic nature of
our study design, patients had large differences in follow-up periods between
assessments. To enhance comparability, the time horizon to assess QALYs and costs, was
set at one year after the baseline measurement (T1) for each individual patient.

Healthcare and non-healthcare costs
Table 1 shows the estimated total mean healthcare and non-healthcare costs per patient
over the study period. Direct costs associated with the primary treatments (including
psycho- and pharmacotherapy contacts) and crisis contacts were €759 in the concise care
group compared to €655 in the standard care group. This difference was non-significant
(Table 1). Moreover, the non-significant differences in mean number of contacts between
groups are presented in Table 1, Appendix 1. Combined with other hospital costs
(including hospital admission, specialist contacts) and healthcare costs outside the
hospital (i.e. physiotherapy, general practitioner care, alternative medicine, home care)
mean total healthcare costs per patient are €14,761 for concise care and €12,881 for
standard care, which results in a non-significant difference of €1,180 (95% CI -5006 to
1246) between the two treatment groups. Cost due to outpatient visits (see Table 1) were
the greatest contributor to mean total costs. Productivity loss due to absenteeism and
presenteeism moreover resulted in a non-significant difference ( €2915, 95% CI -12453
to 6622) in non-healthcare costs. Societal costs (sum of healthcare + non-healthcare
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costs) over the total study period were approximately €44,366 for concise and €39,570
for standard care, which is a non-significant difference (Table 1).
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Table 1 Mean costs per patient after concise and standard care for a follow-up period of one year.
Concise care (n=93)
%1
Primary treatment 2
Cognitive Behavioural Therapy
Pharmacotherapy
Crisis contacts
General Practitioner (GP)
Ambulatory mental health services
Psychiatrist/psychologist/psychotherapist
Company physician
Outpatient visits
Day care (hospital)
Hospital days
Physical therapist
Social worker
Centre for Drugs and Alcohol Addiction
Paid domestic care
Alternative care
Total Healthcare costs (sd)
Self-help
Absenteeism
Presenteeism
Total non-healthcare costs (sd)
Total societal cost (sd)

80.7
76.3
29.0
8.6
72.8
75.7
52.8
65.1
88.2
26.7
31.0
69.9
33.3
30.8
16.9
79.7
100.0
66.3
66.2
78.6
91.4
100.0

Costs, Euro (€) (±SD)

759 (1498)
679 (1365)
64 (156)
17 (82)
790 (946)
2010 (2282)
1277 (1809)
486 (665)
4327 (3275)
141 (279)
865 (1451)
743 (708)
411 (841)
344 (593)
267 (564)
2341 (2189)
14761 (9431)
2123 (3069)
17806 (21217)
9675 (10664)
29605 (26619)
44366 (32427)

Standard care (n=89)
%1

75.3
71.9
30.3
5.6
71.9
82.7
39.2
60.2
83.0
22.1
29.4
71.5
35.1
28.2
16.9
70.1
100.0
61.4
60.0
84.4
93.2
100.0

Costs, Euro (€) (±SD)

655 (954)
586 (934)
54 (120)
15 (116)
617 (789)
1943 (2028)
1079 (1872)
409 (633)
3657 (3271)
111 (223)
888 (1793)
688 (653)
389 (783)
289 (541)
276 (637)
1880 (2039)
12881 (8715)
1650 (2541)
16466 (20736)
8573 (9022)
26689 (24404)
39570 (29739)

Difference (95% CI)

Costs, Euro (€)

104 (-260 to 468)
93 (- 246 to 432)
10 (-31 to 50)
1 (-28 to 31)
173 (-153 to 499)
68 (-832 to 967)
198 (-636 to 1032)
77 (- 203 to 356)
670 (- 377 to 1716)
31 (-93 to 154)
24 (-823 to 776 )
55 (-218 to 328)
22 (-475 to 519)
55 (-242 to 352)
-9 (-255 to 237)
461 (-265 to 1187)
1880 (-1246 to 5006)
474 (-973 to 1920)
1340 (-5690 to 8369)
1102 (-2479 to 4682)
2915 (-6622 to 12453)
4795 (-6384 to 15975)

Note:Mean costs are presented as mean (±standard deviation [SD]).
1
Percentages of patients who made costs for that item unless stated otherwise; t test for unequal variance corrected for nonresponse with multiple imputation. CI=Confidence Interval.
2
Face to Face, No Show, Telephone and/or email contacts primary treatment.

P-value

0.58
0.59
0.64
0.93
0.29
0.88
0.62
0.58
0.21
0.60
0.95
0.68
0.92
0.70
0.94
0.21
0.23
0.49
0.71
0.54
0.54
0.30

Quality of life
Utility scores were comparable between both conditions during the study period (Figure
1).

Figure 1 Utilities with 95% confidence intervals for concise care and standard care.
Note: T1: baseline assessment; T2: 3 month assessment; T3: 6 month assessment; T4: 12 month assessment.

As a result, total QALYs (SD) over the study period were 0.633 (0.077) for concise care
and 0.628 (0.074) for standard care. The difference in QALYs between concise and
standard care was not statistically different (difference: -0.005; 95% confidence interval 0.032 to 0.022, p=0.73).

Cost Utility Analysis
The cost-effectiveness acceptability curves (CEAC) indicates the probability of concise
care being cost-effective. Analyses indicate that for varying levels of the willingness-topay (WTP) threshold, the probability that concise care is more cost-effective compared to
standard care remains below the turning point of 0.5 (see Figure 2). The CEACs show a
probability below 25% that concise care will be considered cost effective for all values of
the willingness to pay considered acceptable for the Dutch situation.32,33
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Figure 2 Cost-effectiveness acceptability curves for concise care compared with standard care for a follow-up period of one
year.
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Discussion
Main findings
Cost comparisons between concise care and standard care, in the treatment of mild to
moderate depressive and anxiety disorders in secondary mental health care, did not reveal
any significant differences in mean healthcare and societal costs over a study period of
one year. The mean cost of the primary treatments were estimated at €759 and €655
(difference €104; 95% CI - €260 to €468) for concise and standard care respectively.
Also, after considering other healthcare- and non-healthcare cost over the study period,
no significant differences between treatment groups could be detected. In both groups,
most of the healthcare costs were caused by non-psychiatric outpatient visits, supporting
the frequent observation that persons with depressive or anxiety disorders have many
other health problems.34 The QALYs based on the SF36 did not differ significantly
either. Our results demonstrate that the reduction of depression and anxiety symptoms
and improved subdomains of health related quality of life associated with concise care
compared to standard care (see Meuldijk and colleagues)8 were not reflected in the utility
scores and achieved without significant differences in costs. Therefore, this study failed
to demonstrate a favourable cost-utility for concise care in comparison with standard
care. Our results are in line with earlier studies examining cost-effectiveness of brief
psychological treatments.35-37 In most of these studies the differences in total healthcare
costs between brief therapy and standard care were very small and not statistically
significant.
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Limitations
There are certain methodological considerations about our study that need to be
addressed as well. Firstly, the relatively small sample size and the substantial number of
patients who did not complete treatment or were lost to assessment (see Meuldijk (2015)
and collegeaus)8, for which we accounted by Multiple Imputation (MI), is worth noticing.
Although MI is a sophisticated imputation technique, even this method of dealing with
missing data is precarious because of the large amount of missing data in this trial
especially at the final follow up moments.38,39 Secondly, our study was underpowered to
detect relevant cost differences, which is reflected in the wide confidence intervals
around the cost estimates. Unfortunately, this is a common problem in economic
evaluations alongside clinical trials in a natural setting.40 Moreover, the design of the
study as a RCT in a pragmatic setting resulted in considerable differences in follow-up
periods between patients and groups. Therefore, the time horizon for the economic
evaluation was set at one year after baseline measurement. However, this time period of
one year might not be long enough to capture the full costs and the long term effects of
concise care and standard care, and may turn out to be a limitation of this trial. One might
speculate that concise care is completed by the end of the follow-up period while patients
in the standard care group could still be provided with healthcare. It is therefore possible
that the potential savings in concise care were not fully visible after one year and may
need a longer follow-up period. An additional methodological limitation was that in
practice, not all patients were offered concise care as planned in the study protocol.
Although the majority of patients was offered concise care within the first 3 months, the
duration of concise care was prolonged and continued during the entire study period,
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resulting in non-significant higher costs of primary treatment in concise care compared to
standard care in the first year. More strictly adhering the treatment protocol, whereby the
number of sessions is realized as planned in the protocol and within the scheduled timeperiod, could lead to lower costs of concise care. In this situation concise care may help
to reduce waiting lists by the earlier completion of treatment and could be also more
successful in meeting the preferences of the patients.42,43
Finally, study outcomes were assessed by Routine Outcome Monitoring (ROM), a
procedure already in use in the participating outpatient clinics.41 Since ROM is computerbased (touch-screen) and therefore does not allow open answer format questions, some
items of the TiC-P questionnaire were categorized. Respondents had to choose an answer
from a given number of options, which might have resulted in less exact answers.
Moreover, data related to medication use costs were not available for the economic
evaluation because of the open answer format of computer-based measuring.

Implications
However, the pragmatic study design, is also an important strength of this
economic evaluation. It offers an opportunity to evaluate the cost-effectiveness of concise
care under real world conditions, this increases external validity, and greatly enhances the
generalizability of the findings to clinical practice.44,45 We conducted this large-scale
multicenter RCT in the naturalistic clinical setting of routine mental health care services
for secondary care in The Netherlands, reflecting normal day-to-day clinical practice in a
regular ‘real life’ psychiatric outpatient population.
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To our knowledge, this is one of the first studies to assess the cost-utility of
concise care alongside a clinical effectiveness trial in a secondary care setting. According
to our results, symptoms of depressive and anxiety disorders were reduced to a similar
extent and concise and standard care are comparable in terms of costs, no statistically
significant differences in total costs and/or QALYs were found between both groups.
This may be due to inadequate sample sizes for the economic evaluation 1. More research
overcoming the limitations of the current study and a sufficiently long follow-up period
are needed before definite conclusions about the cost-effectiveness of concise care, can
be made. Future studies may give insight how to optimize clinical and cost effectiveness
and increase the quality of secondary mental healthcare.
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Appendix I Table 1 Mean number of sessions of primary treatment for a follow-up period of one year.
Concise care (n=93)

Standard care (n=89)

Number of sessions Primary Treatment1

Mean ( ±SD)

IQR

Median

Range

Mean ( ±SD)

IQR

Median

At 3 months assessment(T2)
Number of sessions Primary Treatment1
Cognitive Behavioural Therapy
Pharmacotherapy
Crisis contacts

10 (20)
8 (17)
1 (4)
0 (2)

2-9
1-8
0-0
0-0

6
5
0
0

0-177
0-145
0-26
0-18

5 (9)
4 (7)
1 (3)
0 (3)

0-7
0-6
0-0
0-0

2
1
0
0

0-47
0-37
0-18
0-31

0.081
0.061
0.283
0.969

At 6 months assessment (T3)
Number of sessions Primary Treatment1
Cognitive Behavioural Therapy
Pharmacotherapy
Crisis contacts

12 (20)
10 (17)
2 (4)
0 (0)

3-14
1-12
0-1
0-0

8
7
0
0

0-177
0-145
0-26
0-18

10 (11)
9 (10)
1 (3)
0 (0)

0-13
0-13
0-1
0-0

8
7
0
0

0-47
0-43
0-18
0-31

0.353
0.376
0.363
0.987

At 12 months assessments (T4)
Number of sessions Primary Treatment1
Cognitive Behavioural Therapy
Pharmacotherapy
Crisis contacts

13 (21)
11 (18)
2 (5)
0 (3)

3-17
1-12
0 -1
0 -0

8
7
0
0

0-177
0-145
0-26
0-18

12 (13)
10 (12)
1 (3)
0 (2)

1-16
0-14
0-1
0-0

9
8
0
0

0-63
0-63
0-18
0-31

0.466
0.617
0.372
0.987

Note: Number of sessions are presented as mean (±standard deviation [SD]), interquartile range (IQR), median, range).
1
Total number of Face to Face, No Show, Telephone and/or email contacts primary treatment.
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Range

P-value

